NCT05707949

Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine

Brief summary

A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. A number of treatments are available for adults with migraine but there are limited approved treatments available for participants less than 18 years of age. The main goal of the study is to evaluate the long-term safety and tolerability of atogepant in pediatric participants between the ages of 6 and 17 with episodic migraine. Atogepant is a medicine currently approved to treat adults with episodic migraine (0 to 14 migraine days per month) and is being studied in pediatric participants between the ages of 6 and 17 with a history of episodic migraine. This is a Phase 3, open-label study of atogepant in participants with a history of episodic migraine. Participants must have completed participation in another study of atogepant (lead-in study) or completed the screening period of that study. Participants must have 4 to 14 migraine days and less than 15 headache days in the 4-week screening electronic diary (eDiary; similar to a smart phone). Around 250 participants will be enrolled in the study at approximately 100 sites worldwide. Atogepant is a tablet taken once a day by mouth. Participants between the ages of 12 and 17 will receive high dose atogepant for 52 Weeks. Participants between the ages of 6 and 11 will receive an atogepant dose determined in the lead-in study for 52 Weeks. There may be a bigger responsibility for participants in this study. Participants will attend regular visits during the study at a hospital or clinic. The effects of treatment will be checked by medical assessments, blood tests, checking for side effects, and completing questionnaires.

Interventional study

Status:
Enrolling by invitation
Conditions:
Episodic Migraine
Enrollment:
250 patients
Phase:
  • 1
  • 2
  • 3
  • 4
Protocol ID:
M21-199
Allocation:
Non-Randomized
Intervention model:
Parallel Assignment
Masking:
None (Open Label)
Purpose:
Treatment

Would you like to know more about this trial?

alert image Please note, participation in the clinical trial is open to patients with the disease or condition under investigation.
Yes, please contact me

Eligibility criteria

Participant attributes:
Male and Female

Age:

From 6 Years to 17 Years.

Inclusion Criteria:

- Participants must be between 6 and 17 years of age (inclusive), with a history of
episodic migraine.

- The participant must have completed the lead-in Study M21-201, the pharmacokinetic
(PK) substudy in Study M21-201, or completed the 4-week screening/baseline period and
screen failed due to not meeting the number of migraine day requirements for the
inclusion criteria in Study M21-201, and, in the judgment of the investigator, the
participant is an appropriate candidate to be treated with a daily preventive migraine
treatment with atogepant (not applicable for de novo migraine participants)

- Weight is >= 20 kg (44 lbs) and < 135 kg (298 lbs).

- A history of migraine with or without aura consistent with a diagnosis according to
the International Classification of Headache Disorders, 3rd Edition (ICHD-3; 2018) for
at least 6 months.

Exclusion Criteria:

- History of migraine aura with diplopia or impairment of level of consciousness,
hemiplegic migraine, or retinal migraine as defined by ICHD-3 (2018).

- Have a current diagnosis of chronic migraine as defined by ICHD-3 (2018).

- Have a current diagnosis of new persistent daily headache, trigeminal autonomic
cephalgia (e.g., cluster headache), or painful cranial neuropathy as defined by ICHD-3
(2018).

- Have any clinically significant hematologic, endocrine, pulmonary, renal, hepatic,
gastrointestinal, cardiovascular, or neurologic disease.

All the cities where the clinical studies are located

Montreal - H4A 3J1

Quebec